耐药与敏感卵巢癌组织中microRNA表达差异谱检测及分析  

Differentially microRNA expression detection between chemoresistance and sensitive ovarian cancer tissue and preliminary analysis

作　　者：双婷[1] 吴建磊[1] 朱彥丽 史春雪[3] 张萍[1] 接智慧[1] 常爽[1] 王敏[1] 

机构地区：[1]中国医科大学附属盛京医院妇产科,辽宁沈阳110004 [2]沧州市中心医院,河北沧州061000 [3]沈阳市妇婴医院,辽宁沈阳110014

出　　处：《中国实用妇科与产科杂志》2013年第1期33-37,共5页Chinese Journal of Practical Gynecology and Obstetrics

基　　金：国家自然科学基金(30973189)

摘　　要：目的探讨卵巢浆液性癌化疗耐药与敏感组织中microRNA(miRNA)表达差异及参与卵巢浆液性癌耐药形成的分子机制。方法 2008年8月至2011年8月在中国医科大学附属盛京医院选取化疗耐药与敏感卵巢浆液性癌患者经手术切除的卵巢癌组织标本各4例,分别提取总RNA和miRNA,在miRNA微阵列芯片中杂交检测分析,获得miRNA表达差异谱;利用real-timePCR技术进一步验证化疗耐药与敏感卵巢浆液性癌各4例组织中miRNA表达水平。应用生物信息学软件预测表达差异miRNA可能的靶基因。结果芯片筛选出3个与卵巢浆液性癌耐药相关miRNA,其中2个(has-miR-210与has-miR-1307)表达差异上调,1个(has-miR-134)表达差异下调。Real-timePCR显示has-miR-134、has-miR-210和has-miR-1307表达差异结果与miRNA微阵列芯片结果一致。经过生物信息学预测has-miR-134可能靶基因为MRP1/ABCC1,K-ras,RhoGDI2;has-miR-210可能靶基因为HOXA9,FGFRL1,EFNA3;has-miR-1307可能靶基因为BCL-2,SCN5,CIC。结论 miRNA微阵列分析技术是一种快速、高效的研究生物信息的分子生物学技术;has-miR-134、has-miR-210和has-miR-1307可能通过预测的靶基因参与卵巢浆液性癌耐药形成。Objective To test the microRNA（miRNA） expression of ovarian serous cystadenocarcinoma in both chemore- sistance and sensitive tissue, and to explore the molecular mechanism of drug-resistant in ovarian serous cystadenocarci- noma involved the expression differences of miRNAs. Methods The samples each with 4 cases of tissue chemoresistance and sensitive ovarian serous eystadenoearcinoma were obtained from undergoing surgical resection of ovarian cancer. Total RNA and the small RNAs was extracted and isolated respectively. Hybridization was carried out on miRNA mieroarray chip. Real-time PCR was performed to confirm difference of miRNA expression level results obtained by microarray analy- sis between chemoresistance and sensitive ovarian serous cystadenocarcinoma within 4 cases each. Bioinformatic software was used to predict the possible target genes of each miRNAs which expressed differently. Results Three miRNAs relat- ed chemoresistance have been identified, 2 （has-miR-210, has-miR-1307） of them were up-regulated and 1 （has-miR- 134 ） was down-regulated in ovarian serous eystadenocarcinoma tissues. The results obtained by miRNA microarrays of dif- ferential expression with has-miR-134, has-miR-210, has-miR-1307 were confirmed by real-time PCR. The target genes of has-miR-134 are possibly MRP1 /ABCCI, K-ras, Rho GDI2, after bioinformatics prediction, which of has-miR-210 are possibly HOXA9, FGFRL1, EFNA3 ,which of has-miR-1307 are possibly BCL-2, SCNS, CIC. Conclusion MiRNA microarray analysis has become a fast and efficient molecular biological technology for the study ofbiological information. Has-miR-134, has-miR-210 and has-miR-1307 may participate in the formation of drug-resistant in ovarian serous cystad- enocarcinoma through the target genes predicted.

关 键 词：卵巢肿瘤 耐药 microRNA微阵列芯片 实时监测聚合酶链反应 

分 类 号：R737.3[医药卫生—肿瘤]